RT info:eu-repo/semantics/article
T1 Long-term efficacy of autologous bone marrow mesenchymal stromal cells for treatment of knee osteoarthritis
A1 Lamo-Espinosa, José María
A1 Prósper, Felipe
A1 Blanco, Juan F.
A1 Sánchez-Guijo, Fermín
A1 Alberca, Mercedes
A1 García, Verónica
A1 González-Vallinas Garrachón, Margarita
A1 García-Sancho, Javier
K1 Intraarticular injection
K1 Mesenchymal stem cells
K1 Osteoarthritis
K1 Regenerative medicine
K1 Stem cell therapy
AB Knee osteoarthritis is the most prevalent joint disease and a frequent cause of pain, functional loss and disability. Conventional treatments have demonstrated only modest clinical benefits whereas cell-based therapies have shown encouraging results, but important details, such as dose needed, long-term evolution or number of applications required are scarcely known. Here we have reanalyzed results from two recent pilot trials with autologous bone marrow-derived mesenchymal stromal cells using the Huskisson plot to enhance quantification of efficacy and comparability. We find that cell doses of 10, 40 and 100 million autologous cells per knee provided quite similar healing results and that much of the effect attained 1 year after cell application remained after 2 and 4 years. These results are encouraging because they indicate that, apart from safety and simplicity: (i) the beneficial effect is both significant and sizeable, (ii) it can be achieved with a single injection of cells, and (iii) the effect is perdurable for years.Trial registration: EudraCT 2009-017405-11; NCT02123368. Registered 25 April 2014-Prospectively registered, https://clinicaltrials.gov/ct2/show/NCT02123368?term=02123368&draw=2&rank=1.
PB BioMed Central (BMC)
SN 1479-5876
YR 2021
FD 2021
LK https://uvadoc.uva.es/handle/10324/82008
UL https://uvadoc.uva.es/handle/10324/82008
LA eng
NO J Transl Med, Diciembre 2021, vol. 19, n. 1, p. 506.
NO Producción Científica
DS UVaDOC
RD 04-mar-2026